MedPath

The curative effect evaluation for Yi-Qi Yang-Yin Huo-Xue prescription in treatment of the high risk population of hepatitis B cirrhosis with chronic kidney injury

Not Applicable
Recruiting
Conditions
chronic kidney disease
Registration Number
ITMCTR1900002717
Lead Sponsor
Beijing Ditan Hospital Affiliated to Capital Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Meet the Western medicine diagnosis standard of high risk population with hepatitis B cirrhosis complicated with CKD;
2. Men or women aged 18-65;
3. Meet the syndrome of traditional Chinese medicine belongs to Yin deficiency of liver and kidney, Qi deficiency and blood stasis.
4. Sign the informed consent.

Exclusion Criteria

1. Those who are allergy to the applied components of traditional Chinese medicine;
2. The researchers determined that antiviral treatment should be carried out while the patients themselves did not;
3. Cirrhosis with AKI or HRS;
4. Patients with other hepatophilic virus infection or with autoimmune liver disease, primary biliary cirrhosis, hereditary metabolic liver disease, unrequited alcoholic liver disease and liver transplantation;
5. Uncontrolled hypertension, diabetes, malignant tumor and other serious diseases;
6. Previous renal calculus, chronic glomerulonephritis, nephrotic syndrome, IgA nephropathy, systemic lupus erythematosus, nephrotoxic drug-related renal damage and other kidney diseases;
7. Baseline GFR < 60 ml / (min / 1.73 m2);
8. Women within pregnancy and lactation period;
9. Patients who cannot cooperate.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of CKD;
Secondary Outcome Measures
NameTimeMethod
Child Pugh and MELD scores;Incidence of hepatorenal syndrome;TCM syndrome scores;
© Copyright 2025. All Rights Reserved by MedPath